Durect Details Eladur Study Results

Durect reported results from a Phase IIa trial for Eladur, a transdermal pain patch.

The randomized, multicenter, double-blind, placebo-controlled, two-way, crossover study examined 60 patients suffering from postherpetic neuralgia.

The study assessed the safety, magnitude, duration and characteristics of analgesic activity of the product, which showed improved pain control versus placebo during the three-day continuous treatment period, according to Durect.